Sutro Biopharma's Trevor Hallam offers a glimpse into the future of drug design - - BioPharm International

ADVERTISEMENT

Sutro Biopharma's Trevor Hallam offers a glimpse into the future of drug design


blog comments powered by Disqus


In this final podcast of three, BioPharm International interviews Dr. Trevor Hallam, chief scientific officer at Sutro Biopharma, a company that has developed a cell-free system for protein expression. Dr. Hallam describes where Sutro positions itself in the market and is keen to point out that the goal is to extend what can be designed and manufactured rather than to challenge current CHO- or other cell-based systems already being used efficiently. Exciting areas where such design is increasingly important include oncology or inflammation, where the manufacture of sophisticated molecules, such as antibody-drug conjugates or bi-specifics, is becoming more complex. Dr. Hallam believes the reiterative design made possible by cell-free system opens doors to a future that is unavailable with the limitations of cell-based systems. Posted Dec. 2011.

Podcast 1 on the cell-free protein expression system

Podcast 2 on a future GMP facility

Related article on industrializing design, development, and manufacturing of therapeutic proteins

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here